Relay Therapeutics, Inc. has reported a stock sale by Donald A. Bergstrom, its President of Research and Development. This transaction, filed with the SEC, occurred on October 28, 2026, and involved the sale of 2,252 shares of common stock at a price of $18.62 per share. The sale was executed to cover income tax withholding obligations related to the vesting of restricted stock units (RSUs).

This event is significant as it underscores the ongoing management of employee equity compensation within the company. The transaction reflects Relay Therapeutics' adherence to SEC regulations and its commitment to transparency in executive compensation practices.

Background

Relay Therapeutics, Inc. operates within the biological products industry, specifically categorized under SIC 2836, which includes companies involved in the development and production of biological products (excluding diagnostic substances). The company trades on the Nasdaq under the ticker symbol RLAY. As a large accelerated filer, Relay Therapeutics is subject to stringent reporting requirements, ensuring it maintains a high level of corporate governance.

What the Filing Says

The SEC filing details that Bergstrom sold 2,252 shares to meet tax obligations arising from the vesting of 5,012 RSUs on October 27, 2026. The filing states, "The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs." Following the transaction, Bergstrom retains ownership of 396,878 shares, which includes 5,013 shares underlying RSUs.

Impact

This sale may affect the perception of Relay Therapeutics among investors and analysts, as it highlights the company's approach to managing executive compensation and tax obligations. The transaction is also relevant to other stakeholders in the biological products sector, as it reflects common practices surrounding stock-based compensation in the industry.

What's Next

The filing does not say what happens next.